Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 14:37:100798.
doi: 10.1016/j.lanwpc.2023.100798. eCollection 2023 Aug.

A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji

Rita Reyburn  1 , Evelyn Tuivaga  2 , Tupou Ratu  2 , Seruwaia Young  2 , Suzanne M Garland  1   3   4 , Gerald Murray  1   3   4 , Alyssa Cornall  1   3 , Sepehr Tabrizi  3 , Cattram D Nguyen  1   5 , Kylie Jenkins  1 , Lisi Tikoduadua  2 , Joseph Kado  2 , Mike Kama  2 , Eric Rafai  2 , Rachel Devi  2 , Kim Mulholland  1   6 , James Fong  2 , Fiona M Russell  1   7
Affiliations

A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji

Rita Reyburn et al. Lancet Reg Health West Pac. .

Abstract

Background: In 2008/9, Fiji vaccinated >30,000 girls aged 9-12 years with the quadrivalent human papillomavirus (4vHPV) vaccine coverage for at least one dose was >60% (one dose only was 14%, two dose only was 13%, three doses was 35%). We calculated vaccine effectiveness (VE) of one, two and three doses of 4vHPV against oncogenic HPV genotypes 16/18, eight years following vaccination.

Methods: A retrospective cohort study was undertaken (2015-2019) in pregnant women ≤23 years old, eligible to receive 4vHPV in 2008/9, with confirmed vaccination status. The study was restricted to pregnant women due to the cultural sensitivity of asking about sexual behavior in Fiji. For each participant a clinician collected a questionnaire, vaginal swab and genital warts examination, a median eight (range 6-11) years post vaccination. HPV DNA was detected by molecular methods. Adjusted VE (aVE) against the detection of vaccine HPV genotypes (16/18), the comparison group of non-vaccine genotypes (31/33/35/39/45/51/52/56/58/59/66/68), and genital warts were calculated. Covariates included in the adjusted model were: age, ethnicity and smoking, according to univariate association with any HPV detection.

Findings: Among 822 participants the prevalence of HPV 16/18 in the unvaccinated, one, two and three-dose groups were 13.3% (50/376), 2.5% (4/158), 0% (0/99) and 1.6% (3/189), respectively; and for the non-vaccine high-risk genotypes, the detection rate was similar across dosage groups (33.2%-40.4%, p = 0.321). The aVE against HPV 16/18 for one, two and three doses were 81% (95% CI; 48-93%), 100% (95% CI; 100-100%), and 89% (95% CI; 64-96%), respectively. Prevalence of HPV 16/18 was lower among women with longer time since vaccination.

Interpretations: A single dose 4vHPV vaccine is highly effective against HPV genotypes 16 and 18 eight years following vaccination. Our results provide the longest duration of protection for reduced dose 4vHPV schedule in a low- or middle-income country in the Western Pacific region.

Funding: This study was supported by the Bill & Melinda Gates Foundation and the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government.

Keywords: HPV genotypes 16 and 18; HPV vaccine; Single dose; Vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

RR has nothing to declare. ET has nothing to declare. FTR has nothing to declare. SY has nothing to declare. SMG is a member of the MSD Global HPV Advisory Board, through her institution received an MSD grant for an Investigator Initiated grant and lecture fees for work performed in personal time. She is currently a recipient of an Australian National Health and Medical Research Council Leadership 3 Investigator grant APP1197951. GM has nothing to declare. AC has nothing to declare. ST has nothing to declare. CN is co-investigator on a Merck Investigator Studies Program grant on pneumococcal serotype epidemiology in children with empyema as well as being an investigator on a Pfizer Inc. funded clinical research collaboration of pneumococcal vaccination in Mongolia, both unrelated to this manuscript. KJ has nothing to declare. RD has nothing to declare. KM is a member of the WHO SAGE committee and a co-investigator on the Pfizer-funded study of adult pneumococcal disease burden in Mongolia. JF has nothing to declare. FR receives grant funding from the Australian National Health and Medical Research Council, The Wellcome Trust, the World Health Organization, MCRI, the Bill & Melinda Gates Foundation and the Australian Department of Foreign Affairs and Trade. In the past she has received funds from Gavi, the Vaccine Alliance.

Figures

Fig. 1
Fig. 1
Note, n = 1 for all laboratory assays. ANC = antenatal clinic; VE = vaccine effectiveness; HPV = human papillomavirus; HR = high-risk; LR = low-risk.
See this image and copyright information in PMC

References

    1. Huh W.K., Joura E.A., Giuliano A.R., et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390:2143–2159. - PubMed
    1. Lehtinen M., Lagheden C., Luostarinen T., et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point - registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017;7 - PMC - PubMed
    1. Villa L.L., Costa R.L.R., Petta C.A., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459–1466. - PMC - PubMed
    1. Vesikari T., Brodszki N., Van Damme P., et al. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls. Pediatr Infect Dis J. 2015;34:992–998. - PubMed
    1. Garland S.M., Kjaer S.K., Muñoz N., et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63:519–527. - PMC - PubMed

LinkOut - more resources